Courage Against Cancer
At Courage Against Cancer (CAC), we believe every patient deserves evidence-based answers to the pillar article primary question: Does fenbendazole have a meaningful role in cancer care? Current research exists along a spectrum — from promising laboratory findings to limited human data.
Yes, a limited but growing body of peer-reviewed research exists. Laboratory and preclinical studies have examined fenbendazole’s potential anti-cancer mechanisms — including effects on cell division and glucose metabolism in cancer cells.
At Courage Against Cancer (CAC), we believe patients deserve evidence-based answers to the pillar article’s primary question — does fenbendazole actually support cancer outcomes — starting with the story that launched the conversation. In 2016, an American named Joe Tippens was diagnosed with te…
Fenbendazole, metformin, and ivermectin target colorectal cancer through different mechanisms. Fenbendazole disrupts tubulin, metformin inhibits energy production, and ivermectin blocks drug resistance. While metformin has the strongest human evidence, none have FDA approval for cancer treatment. Ongoing research is needed, and patients should consult their oncology teams for guidance.
This article from Courage Against Cancer evaluates the potential of fenbendazole, a veterinary drug, as a treatment for human colorectal cancer. Despite promising preclinical evidence, there are no conclusive human trials proving its efficacy. Patients are urged to discuss its use with oncologists, as risks such as liver toxicity exist.
At Courage Against Cancer (CAC), we believe cancer patients deserve evidence-based answers to the central question driving this article: What are qualified oncologists and researchers actually saying about fenbendazole in 2026? The short answer is nuanced — scientific interest exists, but formal clinical evidence remains limited.
The article discusses an Expression of Concern issued by Anticancer Research regarding the Hulscher et al. study on ivermectin and mebendazole. It highlights data verifiability issues, the authors’ conflicts of interest tied to The Wellness Company, and how this study differs from credible cancer research, ultimately urging caution for patients evaluating such claims.
Courage Against Cancer clarifies that ivermectin lacks validated clinical evidence as a cancer treatment despite preclinical interest. Major oncology institutions do not endorse it, emphasizing the importance of rigorous evidence-based evaluations. Patients are encouraged to discuss concerns with their oncologists and critically assess claims surrounding off-label treatments.
Courage Against Cancer emphasizes the importance of personalized cancer treatment plans, tailored based on cancer type, stage, and individual patient factors. This guide details various treatment modalities, including chemotherapy, radiation, immunotherapy, hormone therapy, and stem cell transplants, while encouraging patients to engage with their healthcare teams for informed decisions.
Courage Against Cancer emphasizes the importance of distinguishing between the registered trial NCT05318469 and the controversial Hulscher et al. 2026 study. The former aims to assess ivermectin’s safety and efficacy for metastatic triple-negative breast cancer under rigorous oversight, while the latter lacks validated endpoints and ethical scrutiny. Valid results are pending.